SPOTLIGHT -
March 29th 2023
A gut feeling? Researchers analyzed the gut microbiome in major depression disorder and its modulation by SSRI antidepressants.
New results for a study evaluating lumateperone.
March 15th 2023
Study results show that the therapy activates serotonin (5-HT) and improves stress-coping ability.
March 13th 2023
The Future of Mental Health: Ketamine Therapy Report revealed that 55% of Americans who tried at home ketamine took more than the recommended dose.
March 10th 2023
Transcranial direct current stimulation for depression.
Objective Sleep Markers and Suicidal Behaviors
Sleep and suicide: researchers performed a systematic review and meta-analysis of objective sleep markers of suicidal behaviors in patients with psychiatric disorders.
Read More
Views of US Religious Leaders on the Etiology and Treatment of Depression
Researchers analyzed data from the National Survey of Religious Leaders on the state of the psychiatrist-clergy alliance.
Addressing Unmet Needs and Clinical Challenges in MDD
Here are 9 things you need to know about the clinical management of major depressive disorder.
“I’m Just So Tired”: Fatigue in a Medically Complicated Patient
Fatigue is a very common physical complaint. What therapeutic options are available?
Treatment Resistant: Is It a Misnomer?
"The history of medicine is rich in blaming the disease or the patient for 'untreatable' symptoms, until we stumble upon or develop a treatment that is, in fact, effective."
Rx Evolution: An Ununified Model of MDD and Pharmacological Paradigms
The Week in Review: January 23-27
From special issues in diagnosing and treating catatonia to helping justice-involved individuals re-enter the community, here are highlights from the week in Psychiatric Times.
Positive Results from Phase 2a Trial of Psychedelic for Major Depressive Disorder
SPL026 with supportive therapy sees positive results in patients with major depressive disorder.
The Many Faces of Catatonia, An Under-Recognized Clinical Syndrome
Catatonia: learn more about how to best diagnose early.
CRP as a Biomarker of Antidepressant Efficacy
Is inflammation a biomarker of antidepressant efficacy? Researchers analyzed blood CRP levels as a predictor of response to antidepressants.
How to Navigate and Treat ‘New Year Depression’ in Your Patients
There may not be a diagnosis for ‘New Year Depression,’ about 10% to 20% of individuals in the US may get a milder form of these winter blues.
Potentially Treatable Metabolic Abnormalities in Patients with Treatment-Resistant Depression
Metabolic depression? Researchers performed a metabolomic evaluation of patients with treatment-resistant depression.
The Week in Review: December 19-23
From current treatments for cannabis use disorder to new possibilities for the treatment of dementia, here are highlights from the week in Psychiatric Times.
Cariprazine FDA-Approved as Adjunctive Therapy to Antidepressants
Cariprazine is now FDA-approved as an adjunctive therapy to antidepressants.
The Week in Review: December 5-9
From an in-depth analysis of ADHD in clinical practice to differences in effectiveness between intravenous and intranasal ketamine, here are highlights from the week in Psychiatric Times.
Rolling NDA Submission of Zuranolone for MDD, PPD is Completed
This latest submission completes the FDA filing that was initiated in May.
Meta-Analysis of Intravenous vs Intranasal Ketamine
Does route of administration affect antidepressant efficacy of ketamine? Researchers performed a meta-analysis of trials comparing intravenous and intranasal administration.
Hooked on Hype? A Critical Examination of Recent Anti-Antidepressant Reporting
Here’s why most of the claims recently made about antidepressants in Newsweek are wrong.
First TAAR1 Agonist Studied as Adjunctive Therapy for MDD
The first patient in a phase 2/3 study evaluating ulotaront for MDD has been enrolled.
Thinking Beyond the Guidelines: Evidence-Based Novel Therapies for Bipolar Depression
In this CME article, learn how to apply novel treatment approaches for patients with bipolar depression.
Promising New Treatments for Postpartum Depression
Postpartum depression and major depressive disorder in pregnant and postpartum women are severely underdiagnosed and undertreated. How can we more effectively help this patient population?
Watch
Psychiatric Times™ Conference: Clinical Pearls for Treating MDD
Is there one state-of-the-art treatment for depression?
Antidepressants, Placebos, and Lithium—Some Parting Thoughts
In the case of antidepressants, a few recent articles may make it tempting to throw the baby out with the bathwater. But on close examination, that would be a mistake on many levels...
Vitamin D Augmentation in Major Depression With Comorbid Vitamin D Deficiency
D for Depression? Researchers performed a 12-week, randomized, double-blind placebo-controlled trial of vitamin D augmentation for major depression with vitamin D deficiency.
Treating Depression to Prevent Dementia
According to new research, treating depression in older adults could decrease risk of dementia by 51%.
COVID-19 and Mental Health: Global Consequences and CAM Approaches
In this CME article, explore the mental health consequences associated with the COVID-19 pandemic as well as the potential role for complementary and alternative approaches.
Omega-3 Fatty Acids for Depression With Inflammation
“Fishing” for novel approaches to depression: Researchers performed randomized dose-finding trial of omega-3 fatty acids for depression with inflammation.
The Online, At-Home Ketamine Experience: A Clinician’s Dilemma
At-home ketamine treatment initiated by an online provider presents many legal, clinical, and ethical challenges...
Antidepressants Do Not Work by Numbing Emotions
As patients improve with antidepressant treatment, emotional numbing decreases.
Dextromethorphan-Bupropion in Depression
A new—cough, cough—combination treatment for depression. Researchers performed an RCT of dextromethorphan-bupropion in major depressive disorder.